Johnson & Johnson Statement on Nationwide Opioid Settlement Agreement
NEW BRUNSWICK, N.J., July 21, 2021 - Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies today announced the finalization of a nationwide settlement agreement to resolve opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States. As previously announced, the Company will contribute up to $5 billion to the settlement, depending on the number of state and local governments that elect to opt into the agreement over the next several months. "We recognize the opioid crisis is a tremendously complex public health issue, and we have deep sympathy for everyon...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These ac...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
DePuy Synthes Unveils VELYS ™ Robotic-Assisted Solution In Australia: The Next Generation Robotic-Assisted Solution For Knee Replacement Surgery Designed For Use With The ATTUNE® Knee System
Sydney, Australia, July 20, 2021 -- DePuy Synthes, the orthopaedics company of Johnson & Johnson, today announced that Australian orthopaedic surgeons will be among the first in the world to access the next generation of robotics. The VELYS™ Robotic-Assisted Solution, indicated for use with the ATTUNE® Knee System for total knee arthroplasty, has recently been included on the Australian Register of Therapeutic Goods (ARTG).Sue Martin, Managing Director of Johnson & Johnson Medical Australia and New Zealand says: “Australia joins an exclusive list of just a few countries with access to this technology to date. ...
Source: Johnson and Johnson - July 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2021
New Brunswick, NJ (July 19, 2021) – Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2021 of $1.06 per share on the company’s common stock. The dividend is payable on September 7, 2021 to shareholders of record at the close of business on August 24, 2021. The ex-dividend date is August 23, 2021.About Johnson & JohnsonAt Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of ...
Source: Johnson and Johnson - July 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Innovation Announces Extension Of Innovation Partnering Office at Monash University In Collaboration With Victorian State Government To Accelerate The Life-Sciences Hub
MELBOURNE, Australia, July 15, 2021 -- Johnson & Johnson Innovation announced today the extension of the Johnson & Johnson Innovation Partnering Office at Monash University's Clayton Campus in Melbourne (JJIPO@Monash) in collaboration with the Victorian State Government.This joint initiative between Johnson & Johnson Innovation, the Victorian Government and Monash University will be extended for approximately two years through June 30, 2023. The agreement will allow JJIPO@Monash to continue connecting with the Victorian innovation ecosystem, nurturing and accelerating innovative research, new product developmen...
Source: Johnson and Johnson - July 15, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., July 14, 2021 – Interim results from a Phase 1/2a sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization, the length of time evaluated to date. Data showed that T-cell responses – including the important CD8+ T-cells that seek out and destroy infected cells – persisted over the eight-month timeframe examined. The Company announced topline preprint study results from this Phase ...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA ® and AVEENO® Aerosol Sunscreen Products Due to the Presence of Benzene
NEW BRUNSWICK, N.J., JULY 14, 2021 – Johnson & Johnson Consumer Inc. (JJCI) is voluntarily recalling all lots of five NEUTROGENA® and AVEENO® aerosol sunscreen product lines to the consumer level. Internal testing identified low levels of benzene in some samples of the products. Consumers should stop using the affected products and follow the instructions set forth below.The only sunscreen products impacted are aerosol products, specifically: NEUTROGENA® Beach Defense® aerosol sunscreen, NEUTROGENA® Cool Dry Sport aerosol sunscreen,NEUTROGENA® Invisible Daily™ defense aerosol sunscreen,NEUTROGENA® Ultra Shee...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Statement on COVID-19 Vaccine (7/12)
NEW BRUNSWICK, N.J., July 12, 2021 – The safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. While the chance of having this occur is very low, Johnson & Johnson has updated its COVID-19 Vaccine Factsheet to include important information about these rare cases and on the signs and symptoms of Guillain-Barré syndrome. Updates with this new information will be implemented in other regions of the wo...
Source: Johnson and Johnson - July 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Statement on U.S. Government Donations of Company ’s COVID-19 Vaccine
NEW BRUNSWICK, N.J., July 9, 2021 – Johnson & Johnson welcomes the U.S. government’s decision to donate an initial 12 million doses of the Company’s COVID-19 vaccine through the COVAX Facility. The United States is sharing the doses via COVAX to multiple lower-income countries across three continents. The first shipment of 1.5 million doses arrived in Afghanistan on July 9, 2021. In the coming weeks, it is anticipated that the U.S. will allocate a second tranche of Johnson & Johnson COVID-19 vaccines to additional lower-income countries. Separately, the U.S. has already donated 8 million doses of the Company...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Launches Network of Global Health Discovery Centers that Aim to Speed Up Science and Tackle Pandemic Threats
NEW BRUNSWICK, N.J., July 9, 2021 – Johnson & Johnson (the Company) today announced the launch of the J&J Centers for Global Health Discovery (J&J Centers), a new, global network of unique research partnerships that will leverage the institutional strengths of Johnson & Johnson and leading academic institutions to accelerate discovery research to address the world’s most pressing global health challenges. The first J&J Satellite Center for Global Health Discovery (Satellite Center) was launched at the London School of Hygiene & Tropical Medicine (LSHTM) at an event co-hosted by Johnson & Jo...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Reaches Opioid Settlement Agreement with New York State Consistent with Terms of Previously Announced Broader Settlement Agreement in Principle
June 26, 2021 – Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies today announced a settlement agreement with the State of New York and its participating subdivisions, including Nassau County and Suffolk County, resolving their opioid-related claims against the Company. With this agreement, the Company is removed from the trial scheduled to begin in Suffolk County on June 28, 2021. The settlement will provide New York and its participating subdivisions with up to $263 million in funding to address opioid related issues, as well as reimbursement for attorney fees and costs. The settlement is not an...
Source: Johnson and Johnson - June 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Medical Announces Strategic Partnership With Aussie Startup Navbit To Bring Smartphone-Inspired Tech To Hip Replacement Surgery
Sydney, Australia, June 24, 2021 – DePuy Synthes in Australia, a business unit of Johnson & Johnson Medical Pty Ltd, today announced it has entered into an exclusive agreement with Australian start-up Navbit to introduce the Navbit Sprint into operating theatres across the country. The Australian-made innovation is a compact, single use medical device designed to assist surgeons in placing and aligning the acetabular cup, a component that is placed into the hip socket during joint replacement surgery. It uses smartphone-like GPS technology to provide real-time feedback to the surgeon on the position of the cup throug...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
